These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 18312292)

  • 21. Analysis of the HIV-2 protease's adaptation to various ligands: characterization of backbone asymmetry using a structural alphabet.
    Triki D; Cano Contreras ME; Flatters D; Visseaux B; Descamps D; Camproux AC; Regad L
    Sci Rep; 2018 Jan; 8(1):710. PubMed ID: 29335428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An unexpected diagnosis of human immunodeficiency virus-2 infection in an overseas visitor: a case report.
    Sohail A; Van Leer L; Holmes N
    BMC Res Notes; 2017 Mar; 10(1):116. PubMed ID: 28259182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Approved Antiviral Drugs over the Past 50 Years.
    De Clercq E; Li G
    Clin Microbiol Rev; 2016 Jul; 29(3):695-747. PubMed ID: 27281742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort.
    Balestre E; Ekouevi DK; Tchounga B; Eholie SP; Messou E; Sawadogo A; Thiébaut R; May MT; Sterne JA; Dabis F;
    J Int AIDS Soc; 2016; 19(1):20044. PubMed ID: 26861115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System.
    Mahdi M; Szojka Z; Mótyán JA; Tőzsér J
    Viruses; 2015 Nov; 7(12):6152-62. PubMed ID: 26633459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors.
    Raugi DN; Smith RA; Gottlieb GS;
    J Virol; 2016 Jan; 90(2):1062-9. PubMed ID: 26559830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations Proximal to Sites of Autoproteolysis and the α-Helix That Co-evolve under Drug Pressure Modulate the Autoprocessing and Vitality of HIV-1 Protease.
    Louis JM; Deshmukh L; Sayer JM; Aniana A; Clore GM
    Biochemistry; 2015 Sep; 54(35):5414-24. PubMed ID: 26266692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the IeDEA West Africa Collaboration.
    Ekouévi DK; Avettand-Fènoël V; Tchounga BK; Coffie PA; Sawadogo A; Minta D; Minga A; Eholie SP; Plantier JC; Damond F; Dabis F; Rouzioux C;
    PLoS One; 2015; 10(6):e0129886. PubMed ID: 26111242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly resistant HIV-1 proteases and strategies for their inhibition.
    Weber IT; Kneller DW; Wong-Sam A
    Future Med Chem; 2015; 7(8):1023-38. PubMed ID: 26062399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV protease inhibitors: a review of molecular selectivity and toxicity.
    Lv Z; Chu Y; Wang Y
    HIV AIDS (Auckl); 2015; 7():95-104. PubMed ID: 25897264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A modular system to evaluate the efficacy of protease inhibitors against HIV-2.
    Mahdi M; Matúz K; Tóth F; Tőzsér J
    PLoS One; 2014; 9(11):e113221. PubMed ID: 25419967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.
    Chen J; Liang Z; Wang W; Yi C; Zhang S; Zhang Q
    Sci Rep; 2014 Nov; 4():6872. PubMed ID: 25362963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.
    Deuzing IP; Charpentier C; Wright DW; Matheron S; Paton J; Frentz D; van de Vijver DA; Coveney PV; Descamps D; ; Boucher CA; Beerens N
    J Virol; 2015 Jan; 89(1):833-43. PubMed ID: 25355888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacterial proteases: targets for diagnostics and therapy.
    Kaman WE; Hays JP; Endtz HP; Bikker FJ
    Eur J Clin Microbiol Infect Dis; 2014 Jul; 33(7):1081-7. PubMed ID: 24535571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.
    Raugi DN; Smith RA; Ba S; Toure M; Traore F; Sall F; Pan C; Blankenship L; Montano A; Olson J; Dia Badiane NM; Mullins JI; Kiviat NB; Hawes SE; Sow PS; Gottlieb GS;
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2751-60. PubMed ID: 23571535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.
    Mittal S; Bandaranayake RM; King NM; Prabu-Jeyabalan M; Nalam MN; Nalivaika EA; Yilmaz NK; Schiffer CA
    J Virol; 2013 Apr; 87(8):4176-84. PubMed ID: 23365446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention.
    Stefanidou M; Herrera C; Armanasco N; Shattock RJ
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4381-90. PubMed ID: 22664974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of dissociative inhibition of HIV protease and its autoprocessing from a precursor.
    Sayer JM; Aniana A; Louis JM
    J Mol Biol; 2012 Sep; 422(2):230-44. PubMed ID: 22659320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.
    Tie Y; Wang YF; Boross PI; Chiu TY; Ghosh AK; Tozser J; Louis JM; Harrison RW; Weber IT
    Protein Sci; 2012 Mar; 21(3):339-50. PubMed ID: 22238126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative studies on retroviral proteases: substrate specificity.
    Tözsér J
    Viruses; 2010 Jan; 2(1):147-165. PubMed ID: 21994605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.